Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Apply
Peluntamig
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step